# AMBQ earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/AMBQ) · [Earnings tab](https://www.lopjlb.com/stock/AMBQ?tab=earnings) Updated: 2026-07-20T02:00:32 Quarters analyzed: 3 ## Cross-quarter narrative Across the three earnings calls Ambiq Micro moved from a modest revenue base with improving demand in Q2 2025 to its strongest sales in Q4 2025 and a robust Q1 2026 driven by Edge‑AI interest. Gross margin rose from roughly 43% to about 45% before flattening, while operating expenses jumped after a $30 M OpEx increase and continued heavy R&D spend. The company broadened its product portfolio with AI‑focused SoCs, new Apollo and Atomic variants, and the Helia line, yet several roadmap items remain at risk, notably the Atomic fourth‑family and long‑term SPOT licensing. Customer concentration stayed high, with wearables and the top three accounts accounting for the majority of revenue, and supply‑chain headwinds surfaced as fab pricing and lead‑time constraints. Geographic diversification away from China introduced both upside and uncertainty. Profitability timing slipped as cash‑flow breakeven targets remain unmet, pushing breakeven outlook toward 2027‑2028. Overall, demand and margins improved, but cost pressure, concentration risk, and execution uncertainty intensified. ## Latest CallCard · Q1 Ambiq Micro sees strong Q1 growth driven by Edge AI demand, raises Q2 outlook, but faces profitability timing, margin pressure and supply lead‑time constraints. **Guidance:** raised — Management raised guidance, projecting ~75% YoY sales growth in Q2 and a higher baseline for 2026. **Tone:** mgmt 0.8 · Q&A pressure 0.6 · divergence 0.3 Prepared remarks highlighted exceptional momentum, outpacing expectations and net sales exceeding guidance with strong YoY growth. ### Demand visibility Clear visibility into Q2 demand from multiple customer launches Management cites strong end‑user demand, upcoming product launches, a new global customer entering mass production, and expanding non‑wearable pipeline. ### Margins / costs Margins expected to be flat, with modest upside offset by industry cost pressures Non‑GAAP gross margin projected 45‑46% in Q2, with yield improvements but higher substrate and part costs limiting upside. ### Capital allocation Investing heavily in R&D and IP to accelerate product roadmap R&D up 43% YoY, $1.7M IP purchases this quarter, and $21‑22M operating expense forecast to fund Apollo 340, Atomic 110/120 development and go‑to‑market initiatives. ### Milestones - **Apollo 340** [on_track]: In design now; sampling expected first half of next year with revenue materializing in 2028. - **Atomic 110** [on_track]: Tape‑out targeted end of this year; initial customer ramp expected late 2027. - **Atomic 120** [on_track]: Engaged with several alpha customers; strong interest especially for smart glasses. - **Compression Kit** [new]: Currently restricted to Ambiq products; may be offered to other systems in the future. - **New scaled global customer** [new]: Entered mass production this year, adding to revenue base. - **Medical/Industrial/Smart‑Home expansion** [on_track]: Revenue from these segments expected to more than double in 2026. - **Next‑gen design win for large customer** [new]: Design win slated for production in 2027. - **Apollo 5 ramp** [on_track]: Ramping contributes increasing unit shipments and ASP uplift. ### Fears / risks - **Profitability timing**: Revenue needed for cash‑flow breakeven (~$47M per quarter) exceeds current guidance, delaying profitability to possibly early 2028 or H2 2027. - **Margin pressure**: Industry‑wide substrate and part cost increases could offset yield‑related margin improvements. - **Supply constraints**: Rapid market growth creates short lead‑time requests that TSMC/OSAT partners may struggle to fulfill. - **Customer concentration**: Top three customers still represent ~71% of Q1 2026 sales, posing concentration risk. - **Product roadmap execution**: Successful tape‑out and ramp of Atomic 110/120 and Apollo 340 are critical to sustain growth. - **Non‑wearable market adoption**: While non‑wearable pipeline is ~25% of funnel, sustaining 100% QoQ growth may be challenging. - **Pricing power**: Ability to pass on industry cost increases to customers is uncertain despite strong demand. - **Competitive pricing**: Need to balance ASP uplift with competitive pricing to win business. ### Key quotes > “We have started 2026 with exceptional momentum. The market for Edge AI is growing rapidly and is outpacing our expectations from the start of the year.” — Fumihide Esaka > “We expect to sample in the first half of next year. We expect initial customer ramps towards the end of next year and then more meaningful revenue in 2028.” — Jeffrey Winzeler ## Quarter one-liners - **2026 Q1:** Ambiq Micro sees strong Q1 growth driven by Edge AI demand, raises Q2 outlook, but faces profitability timing, margin pressure and supply lead‑time constraints. - **2025 Q4:** Ambiq Micro delivered its strongest Q4 sales, lifted margins and announced new AI‑focused products while flagging longer design cycles and fab pricing as near‑term headwinds. - **2025 Q2:** Ambiq posted Q2 revenue of $17.9 M, improved gross margin, highlighted new Apollo510B launch, Whoop win, and SPOT licensing plans, while noting tariff upside and a 3‑5 year timeline for Atomic and IP licensing. ## Theme arcs - **Demand strength** (improving): Q2 demand improving, Q4 strongest sales, Q1 strong growth driven by Edge AI - **Gross margin** (improving): Margin rose from ~43% to ~45% then expected flat, with modest upside - **Operating expense volatility** (deteriorating): OpEx increased ~$30M in Q4 and project‑based spikes in Q1 - **Customer concentration** (deteriorating): Wearables remain majority and top three customers ~71% of sales - **Supply chain cost pressure** (deteriorating): Fab capacity price hikes and lead‑time constraints noted in Q4 and Q1 - **Product roadmap expansion** (new): Launches of Apollo 340, Atomic 110/120, Helia, Compression Kit and AI‑focused products - **Product development risk** (deteriorating): Atomic fourth family at risk and roadmap execution critical - **Licensing timeline** (new): SPOT IP licensing projected over 3‑5 years - **Tariff uncertainty** (new): Potential upside from tariffs but risk of future order suppression - **Profitability timing** (deteriorating): Cash‑flow breakeven target of $47M per quarter not yet met, delaying profitability ## Guidance path 2025 Q2:maintained → 2025 Q4:maintained → 2026 Q1:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/AMBQ`